CDT Equity (NASDAQ:CDT) Issues Quarterly Earnings Results

CDT Equity (NASDAQ:CDT) issued its quarterly earnings data on Wednesday. The company reported ($8.71) earnings per share for the quarter, Zacks reports.

CDT Equity Trading Down 1.0%

Shares of CDT stock traded down $0.03 on Wednesday, reaching $2.93. 18,708 shares of the company’s stock were exchanged, compared to its average volume of 299,725. CDT Equity has a 52 week low of $2.53 and a 52 week high of $3,700.00. The stock has a market capitalization of $1.85 million, a PE ratio of -0.00 and a beta of 1.52. The company’s fifty day simple moving average is $5.43 and its 200 day simple moving average is $78.79.

Analysts Set New Price Targets

A number of brokerages have recently commented on CDT. Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen upgraded CDT Equity from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, CDT Equity has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.